Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation
- Conditions
- Liver TransplantationHepatocellular CarcinomaMagnetic Resonance Imaging
- Interventions
- Other: Risk model of tumor relapse
- Registration Number
- NCT03981848
- Lead Sponsor
- Zhejiang University
- Brief Summary
The purpose of this study is to establish a non-invasive radiomics method to filter high recurrent-risk liver transplantation recipient population
- Detailed Description
Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Liver transplantation is the most effective treatment for HCC and is in high demand in China. However, recurrence of HCC among liver transplantation recipients is still a great challenge and threat to the survival of recipients. So it is of great significance to establish a non-invasive way to filter high liver transplantation recipient population before transplantation. Based on large scales of pre-treatment MR images, the investigator's study aims to establish a non-invasive radiomics method to filter high recurrent-risk liver transplantation recipient population. This study will contribute to the precise selection of HCC-related liver transplantation recipients.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
- All patients had postoperative pathological diagnosis of HCC
- All patients had underwent contrast-enhanced MRI scan within 2 weeks before liver transplantation
- patients whose pathological diagnosis is not HCC
- patients whose CT images were affected by strong imaging artifacts, i.e. artifacts obscuring more than 10% of whole volume of interest
- patients whose clinical data or CT images were missing
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Non-relapse Risk model of tumor relapse Non-relapse of tumor within two years after liver transplantation Relapse Risk model of tumor relapse Relapse of tumor within two years after liver transplantation
- Primary Outcome Measures
Name Time Method tumor recurrent status two years
- Secondary Outcome Measures
Name Time Method